53,124 Shares in Grail, Inc. (NASDAQ:GRAL) Purchased by Eagle Health Investments LP

Eagle Health Investments LP purchased a new position in Grail, Inc. (NASDAQ:GRAL - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 53,124 shares of the company's stock, valued at approximately $948,000. Grail accounts for about 0.2% of Eagle Health Investments LP's investment portfolio, making the stock its 18th largest position. Eagle Health Investments LP owned 0.16% of Grail at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. FNY Investment Advisers LLC bought a new position in shares of Grail in the fourth quarter worth approximately $26,000. Lindbrook Capital LLC bought a new position in shares of Grail during the 4th quarter valued at approximately $28,000. Wellington Shields Capital Management LLC purchased a new stake in Grail in the 4th quarter worth $33,000. New York State Common Retirement Fund purchased a new stake in Grail during the 4th quarter valued at approximately $59,000. Finally, Wilmington Savings Fund Society FSB purchased a new position in shares of Grail during the fourth quarter valued at about $64,000.

Insider Activity

In other news, President Joshua J. Ofman sold 2,109 shares of the stock in a transaction on Friday, March 7th. The shares were sold at an average price of $31.20, for a total value of $65,800.80. Following the sale, the president now owns 559,673 shares in the company, valued at $17,461,797.60. This represents a 0.38 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Aaron Freidin sold 1,816 shares of Grail stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $31.20, for a total value of $56,659.20. Following the transaction, the chief financial officer now owns 335,170 shares of the company's stock, valued at $10,457,304. The trade was a 0.54 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 11,550 shares of company stock worth $360,436 over the last 90 days.

Remove Ads

Grail Stock Down 4.8 %

NASDAQ:GRAL traded down $1.31 during mid-day trading on Monday, reaching $25.63. The company's stock had a trading volume of 488,830 shares, compared to its average volume of 1,217,875. The stock has a fifty day moving average of $34.03 and a 200-day moving average of $22.48. Grail, Inc. has a 1 year low of $12.33 and a 1 year high of $63.99.

Grail (NASDAQ:GRAL - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The company reported ($1.86) EPS for the quarter, beating the consensus estimate of ($4.41) by $2.55. The firm had revenue of $38.25 million for the quarter, compared to analysts' expectations of $35.33 million. As a group, research analysts anticipate that Grail, Inc. will post -15.15 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Morgan Stanley upped their price target on shares of Grail from $16.00 to $20.00 and gave the company an "equal weight" rating in a report on Tuesday, March 18th.

About Grail

GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.